FDA Marketing Clearance

Advanced Medical Solutions Grp PLC
12 August 2004

For release :           07:00, Thursday 12th August, 2004


                      Advanced Medical Solutions Group plc
 510(k) Marketing clearance from FDA for a new silver alginate dressing


Winsford, UK: Advanced Medical Solutions Group plc, (AIM: AMS), ('AMS' or the '
Company'), the global woundcare technology company, today announces that it has
received 510(k) clearance from the US Food & Drug Administration ('FDA') for the
marketing of a new silver alginate woundcare dressing.

The FDA approval allows AMS to sell this new range of products into the US
market and allows the Company to use another silver technology, which
incorporates ionic silver, in its range of calcium alginate products.

Silver is widely recognised as a safe and effective anti-microbial agent for
infection control. The FDA has given clearance for the product to be used for
the management of moderate to heavily exuding, partial to full thickness wounds
including, pressure ulcers, leg ulcers, diabetic ulcers, graft and donor sites,
trauma and post-operative wounds.

Commenting on this announcement, Dr Don Evans, CEO of AMS, stated:

'This clearance demonstrates our ability to develop new technologies to meet the
need of the marketplace. The introduction of this new silver alginate dressing
continues AMS's stated strategy of moving to higher value products, which will
form an increasing part of our portfolio as we move forward.'


                                    - ENDS -


For further information please contact:

Advanced Medical Solutions Group plc             Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                          Tel: [phone]
Mark Court, Mary-Jane Johnson


Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or
through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf.




                      This information is provided by RNS
            The company news service from the London Stock Exchange